R
R. Duncan Hite
Researcher at University of Cincinnati
Publications - 50
Citations - 6642
R. Duncan Hite is an academic researcher from University of Cincinnati. The author has contributed to research in topics: Lung injury & Pulmonary surfactant. The author has an hindex of 21, co-authored 46 publications receiving 5684 citations. Previous affiliations of R. Duncan Hite include Wake Forest University & Cleveland Clinic Lerner Research Institute.
Papers
More filters
Journal ArticleDOI
Comparison of two fluid-management strategies in acute lung injury.
Herbert P. Wiedemann,Arthur P. Wheeler,Gordon R. Bernard,B. Taylor Thompson,Douglas Hayden,Ben deBoisblanc,Alfred F Connors,R. Duncan Hite,Andrea L. Harabin +8 more
TL;DR: A conservative strategy of fluid management using explicit protocols applied for seven days in 1000 patients with acute lung injury improved the chances of death at 60 days and the conservative strategy improved fluid balance during the first seven days.
Journal ArticleDOI
Early intensive care unit mobility therapy in the treatment of acute respiratory failure
Peter E. Morris,Amanda Goad,Clifton Thompson,Karen Taylor,Bethany Harry,Leah Passmore,Amelia Ross,Laura C. Anderson,Shirley Baker,Mary Sanchez,Lauretta Penley,April Howard,Luz Dixon,Susan Leach,Ronald Small,R. Duncan Hite,Edward F. Haponik +16 more
TL;DR: A Mobility Team using a mobility protocol initiated earlier physical therapy that was feasible, safe, did not increase costs, and was associated with decreased intensive care unit and hospital length of stay in survivors who received physical therapy duringintensive care unit treatment compared with patients who received usual care.
Journal ArticleDOI
Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial
Alpha A. Fowler,Jonathon D. Truwit,R. Duncan Hite,Peter E. Morris,Christine DeWilde,Anna Priday,Bernard J. Fisher,Leroy R. Thacker,Ramesh Natarajan,Donald F. Brophy,Robin Sculthorpe,Rahul Nanchal,Aamer Syed,Jamie Sturgill,Greg S. Martin,Jonathan E. Sevransky,Markos Kashiouris,Stella Hamman,Katherine Egan,Andrei Hastings,Wendy Spencer,Shawnda Tench,Omar Mehkri,James Bindas,Abhijit Duggal,Jeanette Graf,Stephanie Zellner,Lynda Yanny,Catherine McPolin,Tonya Hollrith,David W. Kramer,Charles Ojielo,Tessa Damm,Evan Cassity,Aleksandra Wieliczko,Matthew S. Halquist +35 more
TL;DR: In this preliminary study of patients with sepsis and ARDS, a 96-hour infusion of vitamin C compared with placebo did not significantly improve organ dysfunction scores or alter markers of inflammation and vascular injury.
Journal ArticleDOI
Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome
Jonathon D. Truwit,Gordon R. Bernard,Jay S. Steingrub,Michael A. Matthay,Kathleen D. Liu,Timothy E Albertson,Roy G. Brower,Carl Shanholtz,Peter Rock,Ivor S. Douglas,Bennett P. deBoisblanc,Catherine L. Hough,R. Duncan Hite,B. Taylor Thompson +13 more
TL;DR: Rosuvastatin therapy did not improve clinical outcomes in patients with sepsis-associated ARDS and may have contributed to hepatic and renal organ dysfunction, and was not associated with an increased incidence of serum creatine kinase levels that were more than 10 times the upper limit of the normal range.
Journal ArticleDOI
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness
Timothy D. Girard,Matthew C. Exline,Shannon S. Carson,Catherine L. Hough,Peter Rock,Michelle N. Gong,Ivor S. Douglas,Atul Malhotra,Robert L. Owens,Daniel J Feinstein,Babar A. Khan,Margaret A. Pisani,Robert C. Hyzy,Gregory A. Schmidt,William D. Schweickert,R. Duncan Hite,David L. Bowton,Andrew L. Masica,Jennifer L. Thompson,Rameela Chandrasekhar,Rameela Chandrasekhar,Brenda T. Pun,Cayce Strength,Cayce Strength,Leanne M. Boehm,James C. Jackson,Pratik P. Pandharipande,Nathan E. Brummel,Christopher G. Hughes,Mayur B. Patel,Joanna L. Stollings,Gordon R. Bernard,Robert S. Dittus,E. Wesley Ely,Mind-Usa Investigators +34 more
TL;DR: The use of haloperidol or ziprasidone, as compared with placebo, in patients with acute respiratory failure or shock and hypoactive or hyperactive delirium in the ICU did not significantly alter the duration of delirity.